Category Archives: Endocrinology

Rosiglitazone containing Diabetes Medicines Drug Safety Communication

Share

Rosiglitazone-containing Diabetes Medicines: Drug Safety Communication – Removal of Some Prescribing and Dispensing Restrictionsincluding Avandia, Avandamet, Avandaryl, and generics AUDIENCE: Family Care, Endocrinology, Cardiology ISSUE: FDA has determined that recent data for rosiglitazone-containing drugs, such as Avandia, Avandamet, Avandaryl, and … Continue reading

Share
Posted in Cardiology, Endocrinology, Family Practice, FDA 2013, FDA Notice | Tagged , , , , , , , , , , , | Comments Off on Rosiglitazone containing Diabetes Medicines Drug Safety Communication

Incretin Mimetic Drugs for Type 2 Diabetes

Share

Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication – Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas   ¬†AUDIENCE: Gastroenterology, Endocrinology, Oncology, Patient ISSUE: FDA is evaluating unpublished new findings by a group of … Continue reading

Share
Posted in Endocrinology, FDA 2013, FDA Warning, Gastroenterology, Oncology, Patients | Tagged , , , , , , , , | Comments Off on Incretin Mimetic Drugs for Type 2 Diabetes

Sensipar Cinacalcet Hydrochloride Drug Safety Communication

Share

Sensipar (Cinacalcet Hydrochloride): Drug Safety Communication – FDA Suspends Pediatric Clinical Trials After Report Of Death     AUDIENCE: Health Professional, Endocrinology, Pediatrics ISSUE: FDA has stopped all pediatric clinical trials of Sensipar (cinacalcet hydrochloride) after the recent death of … Continue reading

Share
Posted in Clinical Trials, Endocrinology, FDA 2013, FDA Safety Communication, Healthcare Professionals, Pediatrics | Tagged , , , , , , , , | Comments Off on Sensipar Cinacalcet Hydrochloride Drug Safety Communication

Aliskiren containing Medications Drug Safety Comunication

Share

Aliskiren-containing Medications: Drug Safety Comunication – New Warning and Contraindication including: Amturnide (aliskiren hemifumarate, amlodipine besylate, and hydrochlorothiazide) Tekturna (aliskiren hemifumarate) Tekturna HCT (aliskiren hemifumarate and hydrochlorothiazide) Tekamlo (aliskiren hemifumarate and amlodipine besylate) Valturna (aliskiren hemifumarate and valsartan). Valturna will … Continue reading

Share
Posted in Endocrinology, FDA 2012, FDA Safety Communication, Internal Medicine, Pharmacy | Tagged , , , , , , , , , , , , , , , , | Comments Off on Aliskiren containing Medications Drug Safety Comunication

Is Avandia Worth The Risk?

Share

Is Avandia Worth The Risk? There has been several reported deaths from Avandia from heart attacks and strokes but meanwhile the FDA has refused to recall it. they have only recently updated their warnings about the increased risks to patients. … Continue reading

Share
Posted in Avandia, Endocrinology, FDA 2011, FDA Warning | Tagged , , , , , , , , , , , , , , | Comments Off on Is Avandia Worth The Risk?

Reclast zoledronic acid

Share

Reclast (zoledronic acid): Drug Safety Communication – New Contraindication and Updated Warning on Kidney Impairment AUDIENCE: Endocrinology, Pharmacy, Patient ISSUE: FDA notified healthcare professionals and patients of an update to the drug label for Reclast (zoledronic acid) regarding the risk … Continue reading

Share
Posted in Endocrinology, FDA 2011, Pharmacy | Tagged , , , , , | Comments Off on Reclast zoledronic acid